Urinary Protein Analysis in Pre- and Postoperative Cancer Patients

Yokomizo, Kayo; Iijima, Shiro; Sakai, Nobue; Kurihara, Yoshitaka; Hitratsuka, Nobuo; Nagai, Kagami; Iwai, Takehisa; Shiba, Kiyoko

doi:10.1002/jcla.20087

Cited by 6 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An analytical method based on high-performance liquid chromatography with native fluorescence detection [113] offers an alternative to immunoassay. Finally, SDS-PAGE and densitometry quantitation of bands after staining has been used as a fully quantitative approach in several studies [114][115][116] .…”

Section: Biochemical Analysismentioning

confidence: 99%

Uromodulin Biology and Pathophysiology – An Update

Vyleťal

Bleyer

Kmoch

2010

Kidney Blood Press Res

View full text Add to dashboard Cite

Uromodulin (UMOD) is a glycoprotein expressed on the luminal surface of the apical membrane of renal tubular epithelial cells forming the thick ascending limb of Henle. Here, UMOD forms filamentous structures probably ensuring water impermeability and the countercurrent gradient. The multidomain structure, cellular topology of UMOD and clinical consequences associated with UMOD dysfunction, however, suggest that it may be involved in other biological processes such as receptor-mediated endocytosis, mechanosensation of urinary flow, Wnt-signaling, cell cycle regulation and planar cell polarity. A specific, but as yet unidentified, protease(s) releases UMOD into the urine, where it probably contributes to colloid osmotic pressure, retards passage of positively charged electrolytes, prevents urinary tract infection and modulates formation of supersaturated salts and their crystals. UMOD expression, biosynthesis and excretion are regulated in a complex manner, and dysregulation is found in a wide range of pathological conditions. It is strongly reduced or absent in cases with mutations in UMOD, renin, HNF1B and other genetic disorders causing autosomal dominant hyperuricemic nephropathy. In contrast, elevated UMOD excretion may be associated with, and thus predictive of, chronic kidney disease. UMOD analysis is therefore of importance in all conditions with renal involvement and may be useful in the proper classification of renal diseases.

show abstract

Section: Biochemical Analysismentioning

confidence: 99%

Uromodulin Biology and Pathophysiology – An Update

Vyleťal

Bleyer

Kmoch

2010

Kidney Blood Press Res

View full text Add to dashboard Cite

show abstract

“…Blood and urine become more appealing candidates for their potential application in the clinical setting. Multiple groups have demonstrated the feasibility of urine proteomic studies by identifying reproducible patterns of normal urinary protein expression (20, 23, 26, 27).…”

Section: Proteomics: Evolving Technologiesmentioning

confidence: 99%

The proteogenomic path towards biomarker discovery

Sigdel

Sarwal

2008

Pediatric Transplantation

View full text Add to dashboard Cite

The desire for biomarkers for diagnosis and prognosis of diseases has never been greater. With the availability of genome data and an increased availability of proteome data, the discovery of biomarkers has become increasingly feasible. However, the task is daunting and requires collaborations among researchers working in the fields of transplantation, immunology, genetics, molecular biology, biostatistics, and bioinformatics. With the advancement of high throughput omic techniques such as genomics and proteomics (collectively known as proteogenomics), efforts have been made to develop diagnostic tools from new and to-be discovered biomarkers. Yet biomarker validation, particularly in organ transplantation, remains challenging because of the lack of a true gold standard for diagnostic categories and analytical bottlenecks that face highthroughput data deconvolution. Even though microarray technique is relatively mature, proteomics is still growing with regards to data normalization and analysis methods. Study design, sample selection, and rigorous data analysis are the critical issues for biomarker discovery using highthroughout proteogenomic technologies that combine the use and strengths of both genomics and proteomics. In this review, we look into the current status and latest developments in the field of biomarker discovery using genomics and proteomics related to organ transplantation, with an emphasis on the evolution of proteomic technologies. KeywordsBiomarker discovery; proteogenomics; genomics; proteomics; microarray; transplantation; acute rejection; peptidomics A Biomarker: What, why and why not?A biomarker is a gene, protein/peptide or metabolite present in a biological system. It is indicative of a physiological or pathological state that can be recognized or monitored. Monitoring the biomarker thus provides a means for monitoring the disease condition and assists in its diagnosis and prognosis. The additional value of biomarkers lies in the fact that they can correlate with the underlying disease state. Thus, when assessed in biological fluids distant form the actual site of injury, it provides a non-invasive means to follow the underlying disease. A well-known biomarker is serum creatinine, which is a surrogate biomarker for underlying graft injury. Nevertheless, serum creatinine does not meet the criteria for an ideal biomarker for monitoring renal transplant patients as it lacks high specificity (serum creatinine is dependent on muscle mass and hydration status, in the absence of graft injury) and sensitivity (serum creatinine can be elevated with multiple causes of intrinsic and extrinsic graft injury). There is a unmet need of non-invasive which is more specific and sensitive to replace the renal transplant biopsy as the gold-standard. Biomarkers for monitoring graft injury and survival course in the field of solid organ transplantation can be sought with the help of high throughput proteogenomic techniques ( Figure 1).These biomarkers could be a single or a panel of mRNA transcripts,...

show abstract

“…The data related to IL-4 VNTR and BC are very scarce. However, the 1R allele of the IL-4 VNTR has been assigned as a risk factor for malignancy development, and in Taiwan 1R allele of IL-4 VNTR was associated with bladder36 and oral cancers in China 37. In addition, the 1R/2R genotype of IL-4 VNTR increased the risk of developing cervical cancer among North Indian women 38…”

Section: Discussionmentioning

confidence: 99%

<p>The influence of an<em> IL-4</em> variable number tandem repeat (VNTR) polymorphism on breast cancer susceptibility</p>

AL-Eitan¹,

Rababa'h²,

Alghamdi³

et al. 2019

PGPM

View full text Add to dashboard Cite

BackgroundsBreast cancer (BC) is one of the most widespread cancers globally. Understanding the etiology of BC may help in determining the various risk factors involved in its malignancy. Certain genetic mutations are considered to play a key role in increasing the risk of BC.ObjectivesIn this study, we explored the correlation between a variable number tandem repeat (VNTR) polymorphism in the IL-4 gene and BC.MethodsPCR and subsequent gel electrophoresis were used to genotype this variant in 360 Jordanian women (180 BC patients and 180 controls). In addition, phenotype–genotype analysis was carried out.ResultsOur findings illustrate that there is no significant relationship between the variant genotypes in the IL-4 gene and BC among Jordanian females. Other than body mass index and tumor differentiation (p< 0.05), none of the clinical and pathological parameters of BC patients exhibited any association with the variant genotypes.ConclusionsFrom this study, we propose that the IL-4 genetic variant does not impact BC development and progression but that it could influence the disease prognosis.

show abstract

Urinary Protein Analysis in Pre- and Postoperative Cancer Patients

Cited by 6 publications

References 28 publications

Uromodulin Biology and Pathophysiology – An Update

Uromodulin Biology and Pathophysiology – An Update

The proteogenomic path towards biomarker discovery

<p>The influence of an<em> IL-4</em> variable number tandem repeat (VNTR) polymorphism on breast cancer susceptibility</p>

Contact Info

Product

Resources

About